ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019
A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma.
Hugo J A Adams et al.PubMed ↗Publisher ↗
No numbers read from the abstract.